kothari rushabh

Vehicle: Tata Safari Reg No: GJ01WW4225 Complaint no: 5-183497612261 Please help resolve this urgently.

No signs of misuse was there. A clutch system is expected to last tens of thousands of kilometres, not a few months. Extremely disappointed with this unfair handling. Requesting immediate intervention from Tata Motors for a fair technical reassessment and resolution.

📢 @TataMotors – Need urgent support! My brand-new Tata Safari (only 6–7 months old) suffered a sudden failure of both the clutch plate and flywheel. The service centre has rejected warranty claiming “wear and tear,” which is impossible for such a new vehicle.

@DrAmitJoshi_TMC Very well deserved, sir. Congratulations.

Happy to share that , I received best teachers award on occasion of teachers day yesterday at DM residents convocation ceremony .🙏🙏🙏🙏

amazing collective effort from the group.. congratulations 🎊 research which matters and changes practice on the ground.. enough evidence to indicate that OMCT backbone with immunotherapy must be studied in a frontline trial.. @ASCOPost @SuyogCancer @Larvol @drmpk91 @ajoyojohn

@bonestumor @CRSF_IN @DrVijayPatil11 @VanitaNoronha @TheCancerLetter thank you

@rushabh1388 @CRSF_IN @DrVijayPatil11 @VanitaNoronha @TheCancerLetter Many many Congratulations 👏

1/n..Under the aegis of @CRSF_IN and guidance of @DrVijayPatil11, @VanitaNoronha, Dr. Kumar sir, our long-awaited study on Triple Metronomic therapy was published in @TheCancerLetter. Please read and comment. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

@HariMenon68 @CRSF_IN @DrVijayPatil11 @VanitaNoronha @TheCancerLetter thank you sir

@rushabh1388 @CRSF_IN @DrVijayPatil11 @VanitaNoronha @TheCancerLetter Congratulations Rushabh. Good to see a publication coming forth in the field

Phase 3 Study on Triple Metronomic Therapy Now Published in The Cancer Letter - Rushabh Kothari @rushabh1388 @todrashish oncodaily.com/insight/triple… #Cancer #Oncology #Health #Medicine #OncoDaily @CancerWorldmag

After Oral at ASCO 23, this is my first effort to publish an original article in a high-impact factor Journal. It took long but was worth it and full of learning. I will thank my family, mentors, colleagues and friends. x.com/rushabh1388/st…

Efforts to build on this backbone are ongoing. IO with TMC and Platinum+Taxane+TMC are showing promising results. Clinical trials for same are ongoing under CRSF @TataMemorial @ACTREC_TMC

@DrNikitaMehra @RahulBanerjeeMD @BloodJournal Important finding. What dose you recommend?

@RahulBanerjeeMD @BloodJournal I couldn’t agree more!

Fantastic work by @RahulBanerjeeMD et al on a pooled analysis to assess the impact of Dexamethasone dose intensity in NDMM. No differences in survival outcomes were observed b/w patients who received full-dose Dex vs Dex dose reductions. pubmed.ncbi.nlm.nih.gov/39321347/ @BloodJournal

@drakhilkapoor1 @VanitaNoronha @bkmmishra @TMC_Varanasi @NarjustFlorezMD @Bipinesh @dranuj16 @ASCO @IASLC @DrSanjayPopat @DrJNaidoo @LungConnectIN @myESMO @oncodaily @SuyogCancer @JenniferCKing @StephenVLiu Congratulations. You continue to inspire.

Got Young Investigator Award at #WCLC for project aimed to provide insights into the Microbiome of Indian Lung Cancer patients receiving IO. Thanks to my mentors Kumar Sir, @VanitaNoronha Maam and @bkmmishra Sir. @TMC_Varanasi @NarjustFlorezMD @Bipinesh @dranuj16

@bhargava611 @AnantRamaswamy @drakhilkapoor1 @SuyogCancer Is there any data on PARPi in such setting as maintainence?

Our trial to increase survival of advanced gastric cancer patients with addition of chemotherapy drug was unsuccessful, but has an interesting molecular finding in our indian cohort of patients. academic.oup.com/jncics/article… @AnantRamaswamy @drakhilkapoor1 @SuyogCancer

@ElonMNews @Amolpatel_dr Yes

@todrashish @PTarantinoMD How do you sequence, sir? Post cdk4/6i and AI?

@PTarantinoMD exactly the reason its frequently combined with capecitabine in this part of the world..

Performance of single-agent fulvestrant after CDK4/6i in recent randomized trials for HR+/HER2- mBC (median PFS): - postMONARCH: 5.3 months - PACE: 4.8 months - PALMIRA: 3.6 months - MAINTAIN: 2.7 months - CAPItello291: 2.6 months - EMERALD: 1.9 months